Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HERMES ARZNEIMITTEL is a German pharmaceutical and consumer health company focused on self-medication and over-the-counter healthcare products. The company develops, manufactures, and markets a broad portfolio of branded OTC medicines, dietary supplements, dermopharmaceutical products, and selected medical devices, with flagship brands including Biolectra, doc, Aspecton, algovir, Betaisodona, and ANTI BRUMM. It is part of the privately held HERMES Group and operates primarily from Pullach, Germany, with additional presence in Austria and export partnerships across multiple international markets. The business is commercial-stage rather than pipeline-driven, with strong emphasis on brand management, pharmacy channel distribution, and everyday health categories such as musculoskeletal health, respiratory care, wound care, and prevention. HERMES ARZNEIMITTEL is best characterized as an established OTC pharma company rather than a biotech innovator.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HERMES ARZNEIMITTEL.